In light of the exciting developments in the field of targeted SERCA-inhibiting prodrugs, developed by John T. Isaacs, Sören B. Christensen and colleagues in the fight against prostate cancer as well as neovascular tissue in various tumors (Treiman et al., 1998; Denmeade et al., 2003, 2012; Doan et al., 2015; Mahalingam et al., 2016), we review the current state of the studies on SEC62 overexpressing tumors and discuss where, in our opinion, the field should go from here. The gene discussed is SEC62; the disease is prostate cancer.